Tests teclistamab and talquetamab with standard drugs in newly diagnosed multiple myeloma
Compares teclistamab or talquetamab with daratumumab and lenalidomide against standard treatment in myeloma.
Plain-language title generated from the registry record
Registry title: A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Key facts
- Where
- Ann Arbor, Baltimore, Bethesda, Charleston, Charlotte, Charlottesville, Chicago, Cincinnati, Cleveland, Clovis, Columbus, Dallas, Detroit, Duarte, Durham, East Brunswick, East Syracuse, Farmington, Fort Belvoir, Gilbert, Grand Rapids, Hershey, Hollywood, Houston, Irvine, Kansas City, Lake Success, Lebanon, Los Alamitos, Los Angeles, Louisville, Lubbock, Maywood, Mineola, Nashville, New Haven, New York, Newark, Newnan, Norfolk, Novi, Omaha, Orlando, Pittsburgh, Providence, Richmond, Salt Lake City, Santa Fe, Shreveport, Southfield, Tacoma, Tucson, Waukee, Weston, Wilmington, and Winston-Salem, United StatesSee the 67 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Which of these best describes your myeloma treatment so far?
- Have you ever taken lenalidomide (also called Revlimid), a tablet medicine for myeloma?
- Which describes how well you can look after yourself?
- Have you ever had a stem cell transplant using your own cells?
Source: NCT05552222, who can take part
Where in United States
- University of MichiganAnn Arbor, United StatesTaking people
- Johns Hopkins University School of Medicine JHUSOMBaltimore, United StatesTaking people
- Center for Cancer and Blood DisordersBethesda, United StatesTaking people
- MUSC Hollings Cancer CenterCharleston, United StatesTaking people
- Levine Cancer InstituteCharlotte, United StatesTaking people
- Novant HealthCharlotte, United StatesTaking people
- University of VirginiaCharlottesville, United StatesNo longer taking part
- University of Illinois Medical CenterChicago, United StatesTaking people
- Oncology Hematology CareCincinnati, United StatesTaking people
- The Christ Hospital Cancer CenterCincinnati, United StatesTaking people
- University of CincinnatiCincinnati, United StatesTaking people
- Cleveland Clinic - Main CampusCleveland, United StatesTaking people
- University Hospitals Cleveland Medical Center*Cleveland, United StatesTaking people
- UCSF FresnoClovis, United StatesTaking people
- OhioHealthColumbus, United StatesTaking people
- The Ohio State University James Cancer HospitalColumbus, United StatesTaking people
- University of Texas Southwestern Medical CenterDallas, United StatesTaking people
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion)Detroit, United StatesTaking people
- City of Hope - DuarteDuarte, United StatesTaking people
- Durham VAMCDurham, United StatesTaking people
- Astera Cancer CareEast Brunswick, United StatesTaking people
- Hematology-Oncology Associates of CNYEast Syracuse, United StatesTaking people
- University of ConnecticutFarmington, United StatesTaking people
- Alexander T. Augusta Military Medical CenterFort Belvoir, United StatesTaking people
- Banner MD Anderson Cancer CenterGilbert, United StatesTaking people
- Cancer and Hematology Centers of Western Michigan, PCGrand Rapids, United StatesTaking people
- Penn State Milton S Hershey Medical CtrHershey, United StatesTaking people
- Memorial Healthcare SystemHollywood, United StatesTaking people
- Houston Methodist HospitalHouston, United StatesTaking people
- City of Hope Orange County Lennar Foundation Cancer CenterIrvine, United StatesTaking people
- MidAmerica Cancer CareKansas City, United StatesNo longer taking part
- Northwell Health Cancer InstituteLake Success, United StatesTaking people
- Dartmouth Hitchcock Medical CenterLebanon, United StatesTaking people
- Cancer and Blood Specialty ClinicLos Alamitos, United StatesTaking people
- Valkyrie Clinical TrialsLos Angeles, United StatesTaking people
- Norton Cancer InstituteLouisville, United StatesTaking people
- Joe Arrington Cancer Research Treatment CenterLubbock, United StatesTaking people
- Loyola University Medical CenterMaywood, United StatesTaking people
- NYU Langone Hospital - Long IslandMineola, United StatesTaking people
- Henry-Joyce Cancer ClinicNashville, United StatesTaking people
- Yale New Haven HospitalNew Haven, United StatesTaking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesTaking people
- Perlmutter Cancer Center at NYU Langone HealthNew York, United StatesTaking people
- Weill Cornell Medical CollegeNew York, United StatesTaking people
- ChristianaCare Helen F Graham Cancer Center and Research InstituteNewark, United StatesTaking people
- City of Hope Cancer CenterNewnan, United StatesTaking people
- Virginia Oncology Associates - Brock Cancer CenterNorfolk, United StatesTaking people
- Henry Ford Providence Novi HospitalNovi, United StatesTaking people
- Nebraska Cancer SpecialistsOmaha, United StatesTaking people
- University of Nebraska Medical CenterOmaha, United StatesTaking people
- AdventHealth Medical Group Blood & Marrow Transplant at OrlandoOrlando, United StatesTaking people
- Allegheny Health NetworkPittsburgh, United StatesTaking people
- Rhode Island HospitalProvidence, United StatesTaking people
- Richmond VA Medical CenterRichmond, United StatesTaking people
- Virginia Commonwealth University Medical CenterRichmond, United StatesTaking people
- Huntsman Cancer InstituteSalt Lake City, United StatesTaking people
- Utah Cancer SpecialistsSalt Lake City, United StatesTaking people
- CHRISTUS St. Vincent Regional Cancer CenterSanta Fe, United StatesTaking people
- LSUHSC Shreveport Feist-Weiller Cancer CenterShreveport, United StatesTaking people
- Henry Ford Providence Southfield CK Potluri Cancer CenterSouthfield, United StatesTaking people
- Northwest Medical Specialties PLLCTacoma, United StatesTaking people
- University of Arizona Cancer CenterTucson, United StatesTaking people
- University of Iowa Health CareWaukee, United StatesTaking people
- Cleveland Clinic FloridaWeston, United StatesTaking people
- Novant Health Zimmer Cancer InstituteWilmington, United StatesTaking people
- Atrium Health Wake Forest Baptist Comprehensive Cancer CenterWinston-Salem, United StatesTaking people
- Novant Health Forsyth Medical CenterWinston-Salem, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Janssen Research & Development, LLC
- Trial code
- NCT05552222EU 2023-503442-30-00
- Record updated
- 3 November 2026
- Original description
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).Read full original descriptionShow less
A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).
Inclusion: Have a diagnosis of multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria; Be newly diagnosed and not considered a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT) due to: ineligible due to advanced age OR; ineligible due to the presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT OR; deferral of high-dose chemotherapy with ASCT as initial treatment; Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2; A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment; A participant must agree not to plan to father a child while enrolled in this study or within 100 days after the last dose of study treatment.
Exclusion: Received any prior therapy for multiple myeloma or smoldering myeloma other than a short course of corticosteroids (not to exceed total of 160 milligrams [mg] dexamethasone or equivalent). In addition, received a cumulative dose of systemic corticosteroids equivalent to greater than or equals to (>=) 20 mg of dexamethasone within 14 days before randomization; Had a stroke, transient ischemic attack, or seizure within 6 months prior to randomization; Known allergies, hypersensitivity, or intolerance to teclistamab or talquetamab excipients; Myeloma Frailty Index of >=2 with the exception of participants who have a score of 2 based on age alone; Had plasmapheresis within 28 days of randomization; Known contraindications to the use of daratumumab or lenalidomide per local prescribing information.